Trial Profile
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2022
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Obinutuzumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- 01 Nov 2022 Status changed from active, no longer recruiting to completed.
- 29 Jun 2022 Planned End Date changed from 1 Nov 2021 to 1 Nov 2022.
- 29 Jun 2022 Planned primary completion date changed from 1 Nov 2021 to 1 Nov 2022.